2 min read

Cleerly Product Release:  Taking Precision Heart Care to the Next Level

Featured Image

As Cleerly makes its way into the clinical workflow of health systems and providers across the US, we are learning valuable information about how to drive new efficiencies and deliver new insights to our customers.

American Heart Month has arrived and we’re taking the opportunity to introduce several innovations that up the ante in precision heart care.

Cleerly’s latest product release included many user experience refinements in addition to three high-value tools to explore. We invite you to check out a video demonstration of these features from Cleerly’s Chief Medical Officer, Jay Earls, MD to learn more.


Cleerly 2.2.0 allows users to:

Understand Disease Amount

In past versions, plaque volume was represented by the total volume in millimeters cubed - which may be difficult for most people to quickly visualize. We’ve taken the guesswork out of disease quantification by also representing it with a percentage of vessel volume. Cleerly’s Percent Atheroma Volume (PAV) quantifies the amount of plaque as a percentage of the total vessel volume, making it easier for patients (and physicians alike) to understand disease amount.

PAV represents the percentage of the vessel that is full of plaque. To arrive at this number, absolute plaque volume is divided by the total volume of all of the epicardial coronary arteries. This feature also helps normalize the measurement of plaque between women and men, as women often have smaller arteries than men.



Track Disease Progression

Cleerly’s new first-of-its-kind comparison tool tracks patient disease by the amount and type of atherosclerosis (plaque) rather than surrogate tracking over time, as is the case in many clinical environments today. This tool will be paramount in helping evaluate a patient’s disease progression and the efficacy of treatment. If a patient has a prior study which has undergone a Cleerly analysis, we can compare the two studies side-by-side, making it easy to see whether plaque has remained stable, regressed, or progressed between the two time points.

Comparisons may be made by looking at all coronary vessel measurements combined in a per patient basis or individually on a per vessel basis, or even a per plaque basis according to the viewing preferences of the interpreting physician. Users can also view the comparison in terms of total plaque volume or percentage of atheroma volume (PAV) according to their preference for quantifying disease.

Finally, this new tool also indicates whether plaque is calcium dominant or non-calcium dominant, which is valuable in understanding whether the patient is increasing in more dangerous fatty plaque or effectively converting fatty plaque to more stable, calcified plaque with therapy.



Automate Study Workflow

Finally, if you’re an Ambra image sharing customer, this one’s for you. Cleerly’s new version of Ambra Workflow Optimization enhances the automation of study transfers by re-routing traffic appropriately if uploads are paused for any reason. This new mechanism will allow for seamless data transfer and timely processing for each exam.



With increased use of our technology comes valuable new insights and discoveries that inform future innovation. At Cleerly, we are eager to have customers engage with us and share feedback so we can continuously deliver the most valuable tool in your cardiac care program.


Ready to get started?

Request a Demo of Cleerly


When It's Good to Find Something Bad

For the last 50 years, cardiology care has focused on treating symptoms of heart disease, rather than its root cause - atherosclerosis. At Cleerly,...

Read More

New Staging System for Coronary Artery Disease

New research proposes a four-stage system for measuring the progression of cardiovascular disease (CAD) based on atherosclerotic plaque - not...

Read More

How to Reduce the Need for Invasive Procedures

Cleerly is excited to have released our vision statement calling for a new approach to cardiovascular care. It's an important topic - not just for...

Read More